Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryan M Thomas

Showing results (61-70 of 76) with videos related to

Pageof 8
Sort By:
Research and Practice in Thrombosis and Haemostasis|June 21, 2023
Development of a computable phenotype using electronic health records for venous thromboembolism in medical inpatients: the Medical Inpatient Thrombosis and Hemostasis studyRyan M Thomas, Katherine Wilkinson, Insu Koh, et al.
The American Journal of Pathology|April 23, 2016
Isolation of Pancreatic Cancer Cells from a Patient-Derived Xenograft Model Allows for Practical Expansion and Preserved Heterogeneity in CultureKien Pham, Daniel Delitto, Andrea E Knowlton, et al.
BMC Cancer|October 27, 2015
The inflammatory milieu within the pancreatic cancer microenvironment correlates with clinicopathologic parameters, chemoresistance and survivalDaniel Delitto, Brian S Black, Heather L Sorenson, et al.
International Journal of Molecular Sciences|December 6, 2018
Local and Systemic Cytokine Profiling for Pancreatic Ductal Adenocarcinoma to Study Cancer Cachexia in an Era of Precision MedicineMichael H Gerber, Patrick W Underwood, Sarah M Judge, et al.
Future Oncology (London, England)|September 27, 2023
A phase II study of neoadjuvant liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in pancreatic adenocarcinomaRuchi Singhal, Sherise C Rogers, Ji-Hyun Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 16, 2015
Nicotine Reduces Survival via Augmentation of Paracrine HGF-MET Signaling in the Pancreatic Cancer MicroenvironmentDaniel Delitto, Dongyu Zhang, Song Han, et al.
Cancer Immunology, Immunotherapy : CII|October 2, 2015
Downstream mediators of the intratumoral interferon response suppress antitumor immunity, induce gemcitabine resistance and associate with poor survival in human pancreatic cancerDaniel Delitto, Chelsey Perez, Song Han, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|May 31, 2012
Selective reoperation for locally recurrent or metastatic pancreatic ductal adenocarcinoma following primary pancreatic resectionRyan M Thomas, Mark J Truty, Graciela M Nogueras-Gonzalez, et al.
Carcinogenesis|May 31, 2018
Intestinal microbiota enhances pancreatic carcinogenesis in preclinical modelsRyan M Thomas, Raad Z Gharaibeh, Josee Gauthier, et al.
The Oncologist|June 29, 2026
Use of liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in neoadjuvant pancreatic adenocarcinoma: NEO-Nal-IRI trialThomas J George, Tuo Lin, Ibrahim Nassour, et al.
Pageof 8

Showing results (61-70 of 76) with videos related to

Sort By:
Pageof 8
Research and Practice in Thrombosis and Haemostasis|June 21, 2023
Development of a computable phenotype using electronic health records for venous thromboembolism in medical inpatients: the Medical Inpatient Thrombosis and Hemostasis studyRyan M Thomas, Katherine Wilkinson, Insu Koh, et al.
The American Journal of Pathology|April 23, 2016
Isolation of Pancreatic Cancer Cells from a Patient-Derived Xenograft Model Allows for Practical Expansion and Preserved Heterogeneity in CultureKien Pham, Daniel Delitto, Andrea E Knowlton, et al.
BMC Cancer|October 27, 2015
The inflammatory milieu within the pancreatic cancer microenvironment correlates with clinicopathologic parameters, chemoresistance and survivalDaniel Delitto, Brian S Black, Heather L Sorenson, et al.
International Journal of Molecular Sciences|December 6, 2018
Local and Systemic Cytokine Profiling for Pancreatic Ductal Adenocarcinoma to Study Cancer Cachexia in an Era of Precision MedicineMichael H Gerber, Patrick W Underwood, Sarah M Judge, et al.
Future Oncology (London, England)|September 27, 2023
A phase II study of neoadjuvant liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in pancreatic adenocarcinomaRuchi Singhal, Sherise C Rogers, Ji-Hyun Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 16, 2015
Nicotine Reduces Survival via Augmentation of Paracrine HGF-MET Signaling in the Pancreatic Cancer MicroenvironmentDaniel Delitto, Dongyu Zhang, Song Han, et al.
Cancer Immunology, Immunotherapy : CII|October 2, 2015
Downstream mediators of the intratumoral interferon response suppress antitumor immunity, induce gemcitabine resistance and associate with poor survival in human pancreatic cancerDaniel Delitto, Chelsey Perez, Song Han, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|May 31, 2012
Selective reoperation for locally recurrent or metastatic pancreatic ductal adenocarcinoma following primary pancreatic resectionRyan M Thomas, Mark J Truty, Graciela M Nogueras-Gonzalez, et al.
Carcinogenesis|May 31, 2018
Intestinal microbiota enhances pancreatic carcinogenesis in preclinical modelsRyan M Thomas, Raad Z Gharaibeh, Josee Gauthier, et al.
The Oncologist|June 29, 2026
Use of liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in neoadjuvant pancreatic adenocarcinoma: NEO-Nal-IRI trialThomas J George, Tuo Lin, Ibrahim Nassour, et al.
Pageof 8